Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Praxis Precision Medicines ( (PRAX) ) is now available.
On July 17, 2025, Praxis Precision Medicines announced that the U.S. FDA granted breakthrough therapy designation for relutrigine, a treatment for pediatric patients with SCN2A and SCN8A developmental and epileptic encephalopathies. This designation, supported by positive Phase 2 EMBOLD study data, allows for expedited development and review, potentially enhancing the company’s market position in neurological therapies.
The most recent analyst rating on (PRAX) stock is a Buy with a $114.00 price target. To see the full list of analyst forecasts on Praxis Precision Medicines stock, see the PRAX Stock Forecast page.
Spark’s Take on PRAX Stock
According to Spark, TipRanks’ AI Analyst, PRAX is a Neutral.
Praxis Precision Medicines receives a score of 52, driven primarily by significant financial challenges and negative valuation metrics. These issues are partially offset by positive technical indicators and promising corporate developments in its clinical programs. While technical analysis suggests short-term bullish momentum, financial and valuation concerns remain significant. The positive corporate events related to clinical trial progress offer potential upside but do not outweigh the underlying financial risks.
To see Spark’s full report on PRAX stock, click here.
More about Praxis Precision Medicines
Praxis Precision Medicines operates in the pharmaceutical industry, focusing on developing therapies for neurological disorders. The company specializes in sodium channel modulators, targeting conditions such as developmental and epileptic encephalopathies.
Average Trading Volume: 342,111
Technical Sentiment Signal: Buy
Current Market Cap: $1.06B
Learn more about PRAX stock on TipRanks’ Stock Analysis page.